Literature DB >> 2991293

Anti-proliferative effects of 1,2-diphenylethane oestrogens and anti-oestrogens on human breast cancer cells.

R W Hartmann, T Sinchai, G Kranzfelder.   

Abstract

The anti-tumour activities of 1,2-diphenylethane oestrogens (hexoestrol and orthohexoestrol) and anti-oestrogens (metahexoestrol, tetramethylHES, and metatetramethylHES) were studied on the human MCF-7 and MDA-MB-231 breast cancer cell lines. On the E2R-positive MCF-7 cell line, all test compounds exhibited a dose-dependent inhibition of cell proliferation, but no correlation between anti-proliferative activity and binding affinity for the E2R was found. Tested on the E2R-negative MDA-MB-231 cell line, metahexoestrol also showed dose-dependent inhibitory effects, but higher concentrations were necessary than on the MCF-7 cell line. From this it is concluded that the anti-proliferative effect is specific and at least partially mediated via the E2R. Combination of metahexoestrol (10(-6)M) with E2 (10(-9) to 10(-7)M) gave no rescue effect. It is therefore suggested that this compound might be useful for therapy in the presence of high oestrogen levels, i.e. in pre-menopausal patients. The test compounds (10(-8) to 10(-6)M) could rescue the inhibitory effect of tamoxifen (10(-6)M) in a dose-dependent manner, except in the cases of metahexoestrol (10(-6)M) and tetramethylHES (10(-6)M). The latter compound exhibited a strongly additive effect at this concentration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991293     DOI: 10.1007/bf00402497

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

2.  Equilibrium binding of estradiol by uterine cell suspensions and whole uteri in vitro.

Authors:  D Williams; J Gorski
Journal:  Biochemistry       Date:  1974-12-31       Impact factor: 3.162

3.  Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.

Authors:  A E Wakeling; B Valcaccia; E Newboult; L R Green
Journal:  J Steroid Biochem       Date:  1984-01       Impact factor: 4.292

4.  Screening procedure for the development of mammary tumour-inhibiting anti-oestrogens.

Authors:  R W Hartmann
Journal:  Cancer Treat Rev       Date:  1984-03       Impact factor: 12.111

5.  Antiestrogen-binding sites distinct from the estrogen receptor: subecellular localization, ligand specificity, and distribution in tissues of the rat.

Authors:  K Sudo; F J Monsma; B S Katzenellenbogen
Journal:  Endocrinology       Date:  1983-02       Impact factor: 4.736

6.  Antiestrogen treatment of breast cancer: an overview.

Authors:  O H Pearson; A Manni; B M Arafah
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

7.  Physicochemical and genetic evidence for specific antiestrogen binding sites.

Authors:  J C Faye; S Jozan; G Redeuilh; E E Baulieu; F Bayard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

8.  Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7.

Authors:  W Roos; L Oeze; R Löser; U Eppenberger
Journal:  J Natl Cancer Inst       Date:  1983-07       Impact factor: 13.506

9.  Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.

Authors:  C M Taylor; B Blanchard; D T Zava
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

10.  Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle.

Authors:  R L Sutherland; M D Green; R E Hall; R R Reddel; I W Taylor
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05
View more
  2 in total

1.  Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane.

Authors:  W Schwarz; R W Hartmann; J Engel; M R Schneider; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.

Authors:  T Spruss; S Schertl; M R Schneider; R Gust; K Bauer; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.